MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Keros Therapeutics General and Administrative Expenses 2011-2026 | KROS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Keros Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.8 M | 40.8 M | 34.8 M | 27.5 M | 21.3 M | 12.8 M | 3.18 M | 1.58 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.8 M | 1.58 M | 23.6 M |
Quarterly General and Administrative Expenses Keros Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.1 M | 14.5 M | 10.5 M | - | 9.82 M | 9.96 M | 10.3 M | - | 9.15 M | 8.8 M | 7.78 M | - | 6.94 M | 7.45 M | 6.05 M | - | 5.36 M | 5.66 M | 4.27 M | - | 3.55 M | 3.65 M | 1.98 M | - | 972 K | 654 K | 491 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 491 K | 6.57 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
20.7 M | $ 8.48 | 6.0 % | $ 83.8 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Esperion Therapeutics
ESPR
|
166 M | $ 2.19 | 0.92 % | $ 455 M | USA |
 |
Evogene Ltd.
EVGN
|
7.25 M | $ 0.78 | -4.39 % | $ 27.9 M |  Israel |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Genmab A/S
GMAB
|
661 M | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
1.06 B | $ 8.38 | 2.01 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
8.95 M | $ 0.38 | 2.47 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 21.28 | 4.44 % | $ 995 M | USA |
 |
Halozyme Therapeutics
HALO
|
207 M | $ 66.92 | -1.33 % | $ 8.02 B | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
153 M | $ 29.05 | 0.55 % | $ 1.67 B | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
|
Immatics N.V.
IMTX
|
33.8 M | $ 10.87 | 4.17 % | $ 684 M | Germany |
 |
Incyte Corporation
INCY
|
1.38 B | $ 95.33 | -0.77 % | $ 18.6 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
107 M | $ 1.46 | 4.29 % | $ 375 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 2.99 | 2.4 % | $ 4.92 M | Israel |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.2 | 2.82 % | $ 449 M | USA |
 |
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 24.24 | 0.1 % | $ 3.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
25.5 M | $ 1.47 | 4.26 % | $ 235 M | France |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
43.8 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
20.6 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.78 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |